Company Filing History:
2 out of 2 
1 out of 3 Years Active: 2011-2018
Title: Dagmar Zweytick: Innovator in Cancer Treatment
Introduction
Dagmar Zweytick is a notable inventor based in Graz, Austria, who has made significant contributions in the field of cancer treatment. With a total of three patents to his name, his work focuses primarily on isolated peptides that have the potential to revolutionize cancer therapies.
Latest Patents
Zweytick's latest patents are centered around innovative peptides for the treatment of cancer. These peptides consist of 12 to 50 amino acid residues and are characterized by structural elements such as at least two beta-strands, or two alpha-helices, or a combination of both. The design features a net positive charge of +7 or more, making these peptides uniquely effective in their role. Specifically, they incorporate various hydrophobic amino acids and follow a specific arrangement that enhances their cancer-treating capabilities. Importantly, these peptides are devoid of intramolecular disulfide bonds, which further contributes to their specificity and efficacy.
Career Highlights
Throughout his career, Dagmar Zweytick has worked with prestigious organizations, including Newfield Therapeutics Corporation and the Österreichische Akademie Der Wissenschaften. His experience in these institutions has equipped him with a robust background in research and the development of innovative solutions for complex health issues.
Collaborations
In his journey as an inventor, Zweytick has collaborated with esteemed colleagues, notably Karl Lohner and Sabrina Riedl. Their teamwork has likely played a crucial role in the development of his cancer treatment peptides, demonstrating the importance of collaboration in scientific advancements.
Conclusion
Dagmar Zweytick stands as a prominent figure in the realm of cancer treatment innovations. His patents represent a significant leap forward in therapeutic strategies, emphasizing the importance of peptide research. As the field continues to evolve, Zweytick's contributions will undoubtedly influence future advancements in cancer therapy.